FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Articles|January 1, 2007
Bright Idea for Easier JVP Examination
To facilitate the assessment of jugular venous pressure, shine a beam of light tangentially across the skin overlying the jugular vein while the patient's neck muscles are relaxed.
Advertisement
To facilitate the assessment of jugular venous pressure, shine a beam of light tangentially across the skin overlying the jugular vein while the patient's neck muscles are relaxed. The light exposes the pulsations of the internal jugular vein; simultaneous palpation of the internal carotid artery can aid in the identification of venous pulsations.
- Eleni Patrozou, MD
Providence, RI
Advertisement
Related to this article
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
5 FDA Decisions for Primary Care to Know from September 2026
5